cyc 202 has been researched along with bortezomib in 4 studies
| Studies (cyc 202) | Trials (cyc 202) | Recent Studies (post-2010) (cyc 202) | Studies (bortezomib) | Trials (bortezomib) | Recent Studies (post-2010) (bortezomib) |
|---|---|---|---|---|---|
| 979 | 7 | 393 | 6,868 | 860 | 4,753 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Cheng, X; Christ, J; Eisenbrand, G; Merz, KH; Muehlbeyer, S; Thommet, A; Vatter, S; Wölfl, S; Zeller, J | 1 |
| Murakami, H | 1 |
1 review(s) available for cyc 202 and bortezomib
| Article | Year |
|---|---|
[New strategy for the treatment of multiple myeloma].
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Dexamethasone; Drug Design; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Oxides; Prognosis; Protease Inhibitors; Purines; Pyrazines; Roscovitine; Thalidomide; Transplantation Conditioning | 2005 |
3 other study(ies) available for cyc 202 and bortezomib
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Identification of a Water-Soluble Indirubin Derivative as Potent Inhibitor of Insulin-like Growth Factor 1 Receptor through Structural Modification of the Parent Natural Molecule.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Chemistry Techniques, Synthetic; Drug Screening Assays, Antitumor; Humans; Indoles; Oximes; Protein Kinase Inhibitors; Receptor, IGF Type 1; Signal Transduction; Solubility; Structure-Activity Relationship | 2017 |